Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 2
1946 10
1947 10
1948 13
1949 12
1950 15
1951 16
1952 20
1953 19
1954 12
1955 20
1956 9
1957 9
1958 10
1959 8
1960 9
1961 7
1962 7
1963 5
1964 7
1965 2
1966 7
1967 9
1968 9
1969 15
1970 11
1971 18
1972 12
1973 13
1974 25
1975 50
1976 52
1977 38
1978 49
1979 51
1980 63
1981 61
1982 57
1983 76
1984 80
1985 56
1986 62
1987 60
1988 57
1989 47
1990 43
1991 45
1992 58
1993 35
1994 38
1995 34
1996 32
1997 26
1998 35
1999 32
2000 20
2001 23
2002 22
2003 25
2004 14
2005 16
2006 14
2007 14
2008 23
2009 17
2010 18
2011 19
2012 27
2013 22
2014 11
2015 22
2016 28
2017 13
2018 15
2019 18
2020 24
2021 22
2022 15
2023 26
2024 31
2025 17
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,049 results

Results by year

Filters applied: . Clear all
Page 1
Dihydroergotamine (DHE) - Then and Now: A Narrative Review.
Silberstein SD, Shrewsbury SB, Hoekman J. Silberstein SD, et al. Headache. 2020 Jan;60(1):40-57. doi: 10.1111/head.13700. Epub 2019 Nov 17. Headache. 2020. PMID: 31737909 Free PMC article.
OBJECTIVE: To provide a narrative review of clinical development programs for non-oral, non-injectable formulations of dihydroergotamine (DHE) for the treatment of migraine. BACKGROUND: Dihydroergotamine was one of the first "synthetic drugs" developed in the 20th c …
OBJECTIVE: To provide a narrative review of clinical development programs for non-oral, non-injectable formulations of dihydroergotamine …
Dihydroergotamine mesylate nasal spray: an acute treatment option for migraine in adults.
Silvestro M, Orologio I, Tessitore A, Trojsi F, Tedeschi G, Russo A. Silvestro M, et al. Expert Rev Neurother. 2024 Jun;24(6):555-564. doi: 10.1080/14737175.2024.2342446. Epub 2024 Apr 24. Expert Rev Neurother. 2024. PMID: 38655598 Review.
INTRODUCTION: Although the landscape of migraine symptomatic treatment has been enriched by novel effective drugs, it is mandatory to critically reappraise older molecules to ascertain whether they could still represent reliable alternatives in specific endophenotypes of patients …
INTRODUCTION: Although the landscape of migraine symptomatic treatment has been enriched by novel effective drugs, it is mandatory to critic …
The pharmacology of ergotamine and dihydroergotamine.
Silberstein SD. Silberstein SD. Headache. 1997;37 Suppl 1:S15-25. Headache. 1997. PMID: 9009470 Review.
Ergotamine tartrate (ET) was one of the first ergot alkaloids to be isolated. Dihydroergotamine (DHE) is synthesized by reducing an unsaturated bond in ergotamine (E); this modification results in a changed pharmacologic profile. Dihydroergotamine exhibits greater a …
Ergotamine tartrate (ET) was one of the first ergot alkaloids to be isolated. Dihydroergotamine (DHE) is synthesized by reducing an u …
Ergotamine and dihydroergotamine: a review.
Bigal ME, Tepper SJ. Bigal ME, et al. Curr Pain Headache Rep. 2003 Feb;7(1):55-62. doi: 10.1007/s11916-003-0011-7. Curr Pain Headache Rep. 2003. PMID: 12525272 Review.
In contrast, rectal ergotamine was found to have higher efficacy (73% headache relief) than rectal sumatriptan (63% headache relief). Intranasal dihydroergotamine was found to be superior to placebo, but less effective than subcutaneous and intranasal sumatriptan. ...
In contrast, rectal ergotamine was found to have higher efficacy (73% headache relief) than rectal sumatriptan (63% headache relief). Intran …
Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature.
Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Colman I, et al. Ann Emerg Med. 2005 Apr;45(4):393-401. doi: 10.1016/j.annemergmed.2004.07.430. Ann Emerg Med. 2005. PMID: 15795718
RESULTS: From 281 potentially relevant abstracts, 11 studies met the inclusion criteria. Solitary dihydroergotamine use was compared to sumatriptan and phenothiazines in 3 studies; results failed to demonstrate a significant benefit of dihydroergotamine over these t …
RESULTS: From 281 potentially relevant abstracts, 11 studies met the inclusion criteria. Solitary dihydroergotamine use was compared …
Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment.
Dahlöf C, Maassen Van Den Brink A. Dahlöf C, et al. Headache. 2012 Apr;52(4):707-14. doi: 10.1111/j.1526-4610.2012.02124.x. Epub 2012 Mar 22. Headache. 2012. PMID: 22444161 Free article. Review.
The 5-hydroxytryptamine (5-HT) receptor family mediates the effects of several drugs highly effective in migraine primarily by activating 5-HT(1B) , 5-HT(1D) , and 5-HT(1F) receptors. Ergotamine, dihydroergotamine, and methysergide, as well as the "triptan" sumatriptan, ar …
The 5-hydroxytryptamine (5-HT) receptor family mediates the effects of several drugs highly effective in migraine primarily by activating 5- …
Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.
Silberstein SD, McCrory DC. Silberstein SD, et al. Headache. 2003 Feb;43(2):144-66. doi: 10.1046/j.1526-4610.2003.03034.x. Headache. 2003. PMID: 12558771 Review.
Ergotamine and dihydroergotamine share structural similarities with the adrenergic, dopaminergic, and serotonergic neurotransmitters. ...The scientific evidence for efficacy is stronger for dihydroergotamine than for ergotamine. Their wide use is based on long-term …
Ergotamine and dihydroergotamine share structural similarities with the adrenergic, dopaminergic, and serotonergic neurotransmitters. …
Dihydroergotamine: role in the treatment of migraine.
Schürks M. Schürks M. Expert Opin Drug Metab Toxicol. 2009 Sep;5(9):1141-8. doi: 10.1517/17425250903164211. Expert Opin Drug Metab Toxicol. 2009. PMID: 19624283 Review.
BACKGROUND: Dihydroergotamine belongs to the oldest migraine-specific drugs. Mainly used by headache experts today, its properties are unfamiliar to many physicians. OBJECTIVE: To evaluate the modes of administration, effectiveness and safety profile of dihydroergotamin …
BACKGROUND: Dihydroergotamine belongs to the oldest migraine-specific drugs. Mainly used by headache experts today, its properties ar …
MT 300--POZEN: dihydroergotamine mesylate injection.
[No authors listed] [No authors listed] Drugs R D. 2003;4(6):376-7. doi: 10.2165/00126839-200304060-00010. Drugs R D. 2003. PMID: 14584970 Review.
MT 300 is an injectable formulation of dihydroergotamine mesylate (DHE; a serotonin 5-HT1 receptor agonist) that is being developed by POZEN for the acute treatment of migraine. ...The patents have claims regarding liquid pharmaceutical compositions for the treatment of mi …
MT 300 is an injectable formulation of dihydroergotamine mesylate (DHE; a serotonin 5-HT1 receptor agonist) that is being developed b …
Ergotamine, dihydroergotamine: current uses and problems.
Tfelt-Hansen P. Tfelt-Hansen P. Curr Med Res Opin. 2001;17 Suppl 1:s30-4. doi: 10.1185/0300799039117009. Curr Med Res Opin. 2001. PMID: 12463275 Review.
In contrast rectal ergotamine was found to have higher efficacy (73% headache relief) than rectal sumatriptan (63% headache relief). Intranasal dihydroergotamine (DHE) was found superior to placebo but less effective than subcutaneous and intranasal sumatriptan. ...
In contrast rectal ergotamine was found to have higher efficacy (73% headache relief) than rectal sumatriptan (63% headache relief). Intrana …
2,049 results